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Abstract: Although the majority of smooth muscle neoplasms found in the uterus are benign, 
uterine leiomyosarcoma (LMS) is extremely malignant, with high rates of recurrence and 
metastasis. The development of gynecologic tumors is often correlated with secretion of 
female hormone; however, the development of human uterine LMS is not substantially 
correlated with hormonal conditions, and the risk factors are unclearly understood. 
Importantly, a diagnostic-biomarker, which distinguishes malignant human uterine LMS from 
benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to 
analyze risk factors associated with human uterine LMS, in order to establish a clinical 
treatment method. Homozygous deficient mice for a proteasome subunit  1i/LMP2 
spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. 
Defective LMP2 expression in human uterine LMS was demonstrated, but present in human 
LMA. Therefore, loss in LMP2 expression may be one of the risk factors for human uterine 
LMS. LMP2 may be a potential diagnostic-biomarker and targeted- molecule for a new 
therapeutic approach. 
 
Introduction: The uterus, the organ in which the embryo grows, is composed of three layers, 
the uterine endometrium, myometrium and a serous membrane enveloping the uterus, the 
myometrium is composed of smooth muscle. In general, the term uterine tumor refers to an 
epithelial malignant tumor of the uterus, which is roughly classified as a tumor of the uterine 
cervix or the uterine body. Because of the prevalence of screening, uterine cervix cancer is 
decreasing in incidence, and usually detected at an early stage. In contrast, cancer of the 
uterine body is increasing in incidence, and rarely detected at the initial stages. While most 
tumors of the uterine body are adenocarcinomas derived from the subintimal gland, tumors of 
the uterine cervix are classified into squamous cancer and adenocarcinoma. Smooth muscle 
tumors which develop in the myometrium have been traditionally divided into benign LMA 
and malignant LMS based on cytological atypia, mitotic activity and other criteria. Uterine 
LMS is a rare gynecologic malignancy in the female genital tract, having an estimated annual 
incidence of 0.64 per 100,000 women
1
. Uterine LMS accounts for 5% of tumors of the uterine 
body and develops more often in the muscle layer of the uterine body than in the uterine 
cervix
2,3
.
 
Distinguishing uterine LMA from LMS is very difficult, and a diagnosis generally 
requires surgery and cytoscopy. 
A main factor in the development of tumors in the uterine body is the hormonal 
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environment. Patients with uterine body tumors often are unmarried, have never been 
pregnant, and are taking a hormonal agent. The mechanisms by which uterine LMA and LMS 
develop are not yet understood, though tumor that have developed in the myometrium for 
some reason gradually become larger due to the influence of the female hormone, estrogen, 
and generate tumors. However, no correlation between the development of uterine LMS and 
hormonal conditions, and no obvious risk factors have been identified. The prognosis of 
uterine LMS is not good, and the five-year survival rate is approximately 35%
2,3
. It is worth 
noting that, when adjusted for stage and mitotic count, LMS has a significantly worse 
prognosis than carcinosarcoma
4
. As uterine LMS is resistant to chemotherapy and 
radiotherapy, and thus surgical intervention is virtually the only means of treatment, 
developing an efficient adjuvant therapy is expected to improve the prognosis of the disease
5-7
. 
The identification of a risk factor associated with the development of uterine LMS would 
significantly contribute to the development of preventive and therapeutic treatments. 
 
Development of malignant uterine tumor in LMP2-deficient mice: Cytoplasmic 
proteins are mostly degraded by a protease complex, which has many substrates consisting of 
twenty-eight 20 to 30-kDa subunits, referred to as the proteasome
8
. The proteasomal 
degradation pathway is essential for many cellular processes, including the cell cycle, the 
regulation of gene expression, and others. IFN- up-regulates the expression of large numbers 
of responsive genes, proteasome’s subunits, i.e., LMP2, LMP7, and LMP10 are also markedly 
induced by IFN- signal9-13. Here we identify LMP2, a single IFN--responsive gene product, 
as obligatory for tumor surveillance
12
 and demonstrate a tissue-specific role for LMP2 in 
protection from spontaneous neoplasms of the uterus. 
The homozygous deficient mice for LMP2 show tissue- and substrate-dependent 
abnormalities in the biological functions of the proteasome, and impaired functioning of the 
proteasome in the splenocytes or hepatic cells
14
. We found that uterine LMS occurred in 
female LMP2-deficient mice at age 6 months or older, and the incidence at 14 months of age 
was about 40%
15
 (Fig. 1). The curve indicating the incidence in mice is very similar to that 
indicating the incidence of human uterine LMS, which occurs after menopause. Histological 
studies of LMP2-lacking uterine tumors revealed characteristic abnormalities of uterine 
LMS
15
. The tumors lacked lymphoid infiltrates, a sign of immune recognition, and consisted 
of uniform elongated myometrium cells arranged into bundles. The nuclei of the tumor cells 
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varied in size and shape; furthermore, mitosis was frequent, in contrast, the myometrium cells 
of C57BL/6 mice were normal in appearance
15
. Whereas relatively few Ki-67-positive cells, 
the proliferating cells of solid tumors, were observed in the basal cell layer of the normal 
myometrium, most of the basal cells vividly expressed Ki-67 in LMP2-deficient mice
15
. This 
immunological staining indicates abnormal proliferation of the LMP2-lacking cells in the 
basal layer
15
. LMP2-deficient mice that have developed uterine LMS undergo considerable 
weight loss, and then die by 14 months of age
15
 (Fig. 1). The LMP2-deficient mice also 
exhibit skeletal muscle metastasis from uterine LMS. Therefore it is like that LMP2-deficient 
mice with uterine LMS have died of mass effect and metastasis. In general, it is not easy to 
distinguish uterine LMA from LMS, however, in mice, because of such characteristic 
pathological findings, significant weight loss, and exhibition of skeletal muscle metastasis, a 
tumor that develops in the uterus of an LMP2-deficient mouse can be considered malignant, 
i.e., a uterine LMS. 
 
Biological functions of anti-oncogenic factors on uterine leiomyosarcoma: Uterine 
LMS was demonstrated to spontaneously develop in 6-month-old LMP2-deficient mice at 
high frequency. The expression of cell-cycle regulators that are regulated by the IFN- signal 
or proteasome activity was examined under the LMP2-deficient condition. STAT1, having 
been activated by IFN-, significantly induced expression of tumor suppressors such as IRF1, 
which markedly regulates LMP2 gene expression as a transcriptional regulator
16,17
. It was 
examined whether the IFN- signal induces the expression of each subunit of the 
immuno-proteasome, IFR1 and IRF2 in LMP2-deficient mice and the its parental strain, 
C57BL/6. IFN--induced phosphorylation of STAT1 would not be influenced by a lack of 
LMP2, however, the IRF1 expression was markedly reduced in splenocytes derived from 
LMP2-deficient mice in comparison with wild-type mice. Recent reports suggest that function 
of proteasome subunit contributes to mRNA transcriptional activation
18,19
. Accordingly, the 
transcription of Irf1 mRNA may depend on the function of proteasome subunits. Primary 
cultured tumor cells (LMP2-ULMS) were established from the uterine LMS of LMP2- 
deficient mice, the IRF1 expression was also markedly reduced in the LMP2-ULMS. The 
IRF1 reportedly has the inhibiting effects on tumor cell proliferation
17,20,21
. Thus, a lowered 
level of IRF1 resulting from a deficiency in LMP2 might seem to be a risk factor for uterine 
LMS in mice.  
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If the TP53 gene is damaged, tumor suppression is severely reduced. People who inherit 
only one functional copy of the TP53 gene will most likely develop tumors in early adulthood, 
more than 50 percent of human tumors contain a mutation or deletion of the TP53 gene
22
. To 
increase tumor incidence and better assess the role of systemic expression of TP53 in 
responses to initiation of uterine LMS tumorigenesis, LMP2-deficient mice were bred with 
TP53-deficient mice to create Lmp2
-/-
Tp53
-/-
 double knockout mice. Uterine LMS incidence 
and death rates were similar in Lmp2
-/-
Tp53
-/-
 mice and closely matched control 
Lmp2
-/-
Tp53
+/+
 mice. The correlation of defective TP53 function with uterine LMS 
tumorigenesis is unclearly understood. The tumor suppressor, Rb is phosphorylated by a 
complex of Cyclin E/CDK2 and then inactivated, the activity of CDK2 is also negatively 
regulated via degradation of Cyclin E by the proteasome
23-25
. A level of phosphorylated-Rb is 
clearly observed in MEF-lacking LMP2, and the activity of CDK2 for phosphorylation is 
determined to be stronger than that in normal MEFs. However research over all, including 
experiments with gene-deficient mouse models and clinical studies, suggests that defective Rb 
expression does not take part in the onset of uterine LMS
26-28
. 
 
Angiogenic responses by FGFs, VEGF and SCF in murine and human sarcomas.: The 
effects of angiogenic growth factors on the growth, vascular architecture and the downstream 
cytokine signaling of sarcomas are unclearly understood. These are of potential great 
importance since sarcoma, like endothelium, is of mesodermal origin and therefore could 
grow in response to these growth factors. Four human sarcomas (leiomyosarcoma SKN, 
SK-LMS-1, liposarcoma SW872 and fibrosarcoma SW684) and one murine fibrosarcoma 
(KHT) were grown in the immunodeficient mice, BALB/c nu/nu mice and NOD scid mice, 
respectively. Tumor structural vessels, perfused vessels and hypoxia were quantified 
immunohistochemically. Fast-growing murine KHT tumors had a markedly higher number of 
structural vessels compared with the human sarcomas
29
. In both murine and human sarcomas, 
approximately half of the total structural vessels were perfused, and the numbers of perfused 
vessels decreased with increasing tumor volume
29
.  
In vitro, basal mRNA expression of several angiogenic growth factors and their receptors 
differed between three of the human sarcoma cell lines, SKN, SK-LMS-1 and SW872. 
Compared with human leiomyosarcoma SKN cells and SK-LMS-1 cells, untreated SW872 
cells had higher levels of mRNA expression for FGF11, FGF14, angiopoietin, CD105 and 
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VEGFR1
29
. Three sarcoma cell lines were also treated with six angiogenic growth factors 
(FGF1, FGF2, FGF7, FGF10, VEGF and SCF) and a multifunctional factor TGF which 
controls proliferation, differentiation in many cell types, and mRNA expression of 
endogenous FGF family members (FGF1, FGF2, FGF10, FGF11, FGF13 and FGF14) were 
quantitatively measured using Q-RT-PCR at various times following treatments
29
. Again, 
SW872 cells were more responsive to exogenous growth factor treatment compared with 
SKN, SK-LMS-1 cells in terms of the elevation of endogenous FGF mRNA expression. In the 
SW872 cells, all of the exogenous angiogenic growth factor treatments, except for VEGF, 
significantly upregulated endogenous FGF1, FGF2 and FGF14 mRNA expression. The 
human leiomyosarcoma SKN cells and SK-LMS-1 cells, in contrast, only weakly responded 
to exogenous FGF1, FGF7, FGF10 and TGF, but did not respond to VEGF-A. 
 
Perspectives: Uterine LMS mainly develops in the myometrium or endometrial stroma, and 
menstrual anomalies, such as hypermenorrhea and prolonged menstruation, and symptoms 
such as abnormal hemorrhage, hypogastric pain, lumbar pain, and abdominal strains, are 
observed
4
. As in the case of uterine LMA, however, a correlation between the development of 
uterine LMS, the female hormone and hormone receptors has yet to be elucidated
30-31
. A 
recent report showed the LMP2 expression in luminal and glandular epitheliua, placenta villi, 
trophoblastic shells, and arterial endothelial cells
32
. These results implicate LMP2 in the 
invasion of placental villi, degradation of the extracellular matrix, immune tolerance, 
glandular secretion, and angiogenesis
32
. The present study should help to elucidate the 
regulatory role of the proteasome pathway in the implantation of embryos. Risk factors for its 
development however, have not been identified because of the absence of a suitable animal 
model. The LMP2-deficient mouse was the first animal model of spontaneous uterine LMS to 
be established
15
. To demonstrate whether LMP2 is a potential biomarker for distinguishing 
LMS from LMA, we are investigating the reliability and characteristics of LMP2 as a 
diagnostic indicator with several clinical research facilities. The clinical research is yet to be 
concluded, and large-scale clinical studies need to be performed.  
Definitive histological studies must be performed, including the gene-expression profiling 
of several known pro-oncogenic factors as well as factors such as brain-specific polypeptide 
PEP-19 and a transmembrane tyrosine kinase receptor, C-kit
33-35
. The reduced expression of 
calponin h1 transcripts was reported to be associated with uterine LMS, and calponon h1 
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might function as a tumor suppressor in uterine LMS
36,37
. A recent study showed that 
re-expression of human calponin h1 suppressed cell proliferation and tumorigenesis in uterine 
LMS cells
37
. Further research is required to demonstrate the correlative functions of LMP2 
and other anti-oncogenic factors with calponin h1 in the tumorigenesis of uterine LMS. 
Clarification of the correlation between these factors and the development of uterine LMS and 
the identification of specific risk factors may lead to the development of new treatments for 
the disease. Uterine LMS is refractory to chemotherapy and has a poor prognosis. The 
molecular biological and cytological information obtained from LMP2-deficient mice will 
contribute remarkably to the development of preventive methods, a potential diagnostic- 
biomarker, and new therapeutic approaches against uterine LMS. 
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Figure 1. Histological findings of uterine leiomyosarcoma in LMP2-deficient mice: 
Histological findings of myometrium (a) and uterine LMS in LMP2-deficient mice (b). 
Among the histological findings of uterine LMS in LMP2-deficient mice, a cytoskeleton, 
which is characteristic of uterine LMS, is observed. (a and b magnification x200) Panel c, in 
LMP2-deficient females, uterine LMS is observed at 6 months of age. The incidence at age 14 
months is as high as 40%. The curve indicating the incidence of mouse uterine LMS is very 
similar of that indicating the incidence of human uterine LMS, which is observed after 
menopause. In mice with tumors of the uterus, significant weight loss is observed (d). Thus, a 
tumor that develops in the uterus is diagnosed as malignant, i.e., uterine LMS. 
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